Lyell Immunopharma is like a **Kite Pharma (Gilead)** or **Novartis** for 'reprogrammed' T-cell therapies specifically designed to fight solid tumors.

Think of Lyell Immunopharma as developing the 'next-generation' of T-cell therapies, similar to those by **Kite Pharma (Gilead)**, but engineered to overcome exhaustion and effectively target difficult solid tumors.

• LYL797: A T cell product candidate currently in development for the treatment of non-small cell lung cancer and triple-negative breast cancers.
• LYL845: A T cell product candidate in development designed to target multiple solid tumors.
• NY-ESO-1 program: A T cell therapy program being developed in collaboration with GlaxoSmithKline, targeting synovial sarcoma and other solid tumor indications.

Lyell Immunopharma (LYEL) sells primarily to other companies in the pharmaceutical and biotechnology sector, typically through research and development collaborations, licensing agreements, or potential future commercialization partnerships.

Based on the provided information, a major customer and partner is:

• GlaxoSmithKline (Symbol: GSK) - for the NY-ESO-1 program through a research and development collaboration and license agreement.

Lynn Seely, M.D. President and Chief Executive Officer

Dr. Seely has served as Lyell's President and Chief Executive Officer since December 2022. She was previously the President and CEO of Myovant Sciences, Inc., where she oversaw the marketing approval and launch of ORGOVYX for men with advanced prostate cancer and MYFEMBREE for women with uterine fibroids and endometriosis. Prior to Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc., overseeing the development and marketing approval of XTANDI. She also held leadership roles in drug development collaborations with Pfizer Inc. and Astellas Pharma US, Inc. Earlier in her career, she was Vice President of Clinical Development at Corgentech Inc., Cytyc Health Corporation, and ProDuct Health, Inc., a medical device company that was acquired by Cytyc Corporation. Dr. Seely began her industry career at Chiron Corporation. She also previously served as the lead independent director for Blueprint Medicines Corporation, which was acquired by Sanofi.

Smital Shah Chief Financial and Business Officer

Ms. Shah was appointed Lyell's Chief Financial and Business Officer effective March 9, 2026. She brings over two decades of experience in corporate finance, capital markets, and strategic operations within the biopharmaceutical industry. From October 2014 to December 2022, Ms. Shah served as Chief Business and Financial Officer at ProQR Therapeutics (Nasdaq: PRQR), where she was responsible for directing all business functions including finance, communications, commercial strategy, business development, and legal. Prior to ProQR, she managed Gilead Sciences' multi-billion-dollar debt, cash, and investment portfolios. She also worked as an investment banker at Leerink Partners and J.P. Morgan, focusing on capital raising and strategic transactions in the biotechnology space. Earlier in her career, Ms. Shah held various research and development roles at Johnson & Johnson. Ms. Shah served on the Board of Directors of Pliant Therapeutics until June 2025 and as a Board Member and Chair of the Audit Committee at Graphite Bio until its merger with LENZ Therapeutics in March 2024.

Gary Lee, Ph.D. Chief Scientific Officer

Dr. Lee has served as Lyell's Chief Scientific Officer since January 2022. He is a veteran biotech executive with decades of experience leading cell and gene therapy programs for human applications. From October 2018 to January 2022, Dr. Lee was the Chief Scientific Officer at Senti Bio. Prior to that, from August 2005 to October 2018, he held positions of increasing scientific and leadership responsibility at Sangamo Therapeutics, including serving as the Vice President of Cell Therapy where he led the company's T-cell engineering programs.

Stephen Hill, M.B.A. Chief Operating Officer

Mr. Hill serves as the Chief Operating Officer of Lyell Immunopharma. His role involves overseeing the company's operations.

David Shook, M.D. Chief Medical Officer

Dr. Shook was appointed Chief Medical Officer of Lyell Immunopharma on June 9, 2025. He brings deep expertise in cell therapy and has a proven track record of success in leading clinical developments for oncology.

Key Risks to Lyell Immunopharma (LYEL)

1. Clinical Development and Regulatory Approval Risk: Lyell Immunopharma's success heavily depends on the successful outcome of clinical trials for its T-cell product candidates (e.g., LYL797, LYL845, NY-ESO-1) and subsequent regulatory approvals. T-cell therapies, especially for solid tumors, face significant challenges in demonstrating efficacy and safety, leading to high failure rates in clinical development. Failure to achieve positive results in clinical trials or obtain necessary regulatory approvals would prevent the company from commercializing its therapies and generating significant revenue.
2. Intense Competition and Market Adoption Risk: The field of T-cell therapies for solid tumors is highly competitive, with numerous pharmaceutical and biotechnology companies developing similar or competing treatments. Even if Lyell's product candidates are approved, their commercial success will depend on their ability to differentiate themselves from existing and future therapies, achieve favorable market access, and gain widespread adoption by physicians and patients. Competition could also lead to pricing pressures or make it difficult to secure market share.
3. Intellectual Property Protection Risk: As a company relying on novel "ex vivo genetic reprogramming" (Gen-R) and "ex vivo epigenetic reprogramming" (Epi-R) technologies, Lyell Immunopharma's business is highly dependent on its ability to protect its intellectual property. Challenges to its patents, the inability to obtain broad enough patent coverage, or the emergence of competing technologies that do not infringe on its patents could significantly weaken its competitive position and ability to commercialize its innovations.

Lyell Immunopharma (symbol: LYEL) targets several significant addressable markets with its main product candidates.

Non-Small Cell Lung Cancer (NSCLC)

The global non-small cell lung cancer (NSCLC) therapeutics market was valued at approximately USD 20.2 billion in 2024 and is projected to reach USD 53.9 billion by 2034, with a compound annual growth rate (CAGR) of 10.4% from 2025 to 2034. North America held a dominant share of this market, accounting for 44.4% in 2024.

Triple-Negative Breast Cancer (TNBC)

The global triple-negative breast cancer treatment market was estimated at USD 670.5 million in 2024 and is expected to grow to USD 1.04 billion by the end of 2034, expanding at a CAGR of 4.6% over the next ten years. In 2024, North America is projected to account for 42.5% of the global triple-negative breast cancer treatment market share.

Synovial Sarcoma

The global synovial sarcoma treatment market is estimated to be valued at USD 715 million in 2025 and is expected to reach USD 1.25 billion by 2032, exhibiting a CAGR of 8.5% from 2025 to 2032. Another estimate places the global market at USD 2412 million in 2025, forecasting a rise to USD 3470 million by 2032 with a CAGR of 5.4% during 2026-2032. North America held the largest market share, accounting for 41% in 2023.

Melanoma

The global melanoma market is expected to reach USD 7.5 billion by 2029.

Colorectal Cancer (CRC)

The global colorectal cancer market is projected to reach USD 18.34 billion by 2028.

Lyell Immunopharma (NASDAQ: LYEL) is a clinical-stage T-cell reprogramming company focused on developing T-cell therapies for solid tumors and hematologic malignancies. While direct product revenue is not substantial in the immediate term, the anticipated drivers of future revenue growth over the next 2-3 years stem from the advancement of its key pipeline candidates through clinical development and towards potential commercialization.

The primary expected drivers of Lyell Immunopharma's future revenue growth include:

1. Advancement of Ronde-cel (IMPT-314) for Large B-cell Lymphoma (LBCL): Lyell's lead program, ronde-cel (formerly IMPT-314), a dual-targeting CD19/CD20 CAR T-cell therapy, has shown promising Phase 1 data with high overall response and complete response rates in large B-cell lymphoma patients. The company has initiated pivotal trials, including the PiNACLE trial for third-line treatment with a Biologics License Application (BLA) submission anticipated in 2027, and the PiNACLE-H2H Phase 3 head-to-head trial for second-line treatment, which has commenced patient dosing. Positive results from these pivotal trials and subsequent regulatory approval would be the most significant driver of future revenue.
2. Progression of LYL273 for Metastatic Colorectal Cancer: LYL273, a GCC-targeted CAR T-cell candidate, has demonstrated encouraging early clinical data in a Phase 1 US trial for metastatic colorectal cancer, including a 67% overall response rate at dose level 2. The company plans to initiate a pivotal trial for LYL273 in the first half of 2027, signaling its potential as a significant revenue contributor in a high unmet need oncology market.
3. Continued Clinical Development and Indication Expansion of LYL797: LYL797, a ROR1-targeted CAR T-cell product candidate, has shown dose-dependent clinical activity and the ability of CAR T-cells to expand and infiltrate solid tumors in initial Phase 1 trials. Lyell has expanded the evaluation of LYL797 to include ovarian and endometrial cancers and plans to pursue new indications such as multiple myeloma and chronic lymphocytic leukemia. Ongoing positive clinical data and the broadening of its target patient population are crucial for establishing future market opportunities.
4. Advancement of LYL845 (TIL therapy): LYL845, a tumor-infiltrating lymphocyte (TIL) therapy, is currently in Phase 1 clinical development for melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer. Initial clinical and translational data are expected in the second half of 2024. Continued positive data from this program will be vital for its progression to later-stage trials and eventual commercial potential.

Share Issuance

• Lyell Immunopharma raised $425 million through its Initial Public Offering (IPO) in 2021.
• In March 2026, the company closed an additional $50 million tranche of an equity private placement at $25.61 per share, completing a total of approximately $100 million from a July 2025 private placement.
• Lyell registered additional shares of common stock under its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan annually from 2021 to 2026 due to automatic increases.

Inbound Investments

• In 2019, Lyell received $250 million as a combined upfront payment and equity investment from GlaxoSmithKline (GSK) through a research and development collaboration.
• Lyell completed a $100 million equity private placement, with an initial $50 million tranche closing in July 2025 and the second $50 million tranche closing in March 2026 upon achieving a clinical milestone.
• GSK continues to be a significant investor in Lyell, holding 12% of the company as of April (year not specified but around the time of agreement termination).

Outbound Investments

• In November 2025, Lyell acquired exclusive global rights (excluding Greater China) to LYL273, a CAR T-cell therapy for metastatic colorectal cancer, from Innovative Cellular Therapeutics (ICT) for an upfront payment of $40 million in cash and approximately 2 million shares of Lyell common stock, with potential milestone payments up to $820 million.
• The company incurred $66.3 million in acquired in-process research and development (IPR&D) expense related to the LYL273 license acquisition in the fourth quarter and full year 2025.
• Lyell's net loss for the full year 2024 included $87.2 million in acquired in-process research and development (IPR&D) expense as part of its acquisition of ImmPACT Bio USA Inc.

Capital Expenditures

• Lyell anticipates its current cash, cash equivalents, and marketable securities will be sufficient to cover working capital and capital expenditure needs into the second quarter of 2027.
• The company's cash, cash equivalents, and marketable securities were approximately $247.2 million as of December 31, 2025 (excluding a $50 million tranche received in March 2026), down from approximately $383.5 million as of December 31, 2024.
• Capital expenditures are primarily focused on advancing clinical-stage product candidates and core research platforms.